Published in PLoS Genet on March 31, 2006
The epigenomics of cancer. Cell (2007) 30.91
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol (2010) 8.55
SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell (2008) 5.76
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci (2009) 2.80
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol (2007) 2.07
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol (2009) 1.73
Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem (2009) 1.70
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
p53-based cancer therapy. Cold Spring Harb Perspect Biol (2010) 1.62
SIRT6 in DNA repair, metabolism and ageing. J Intern Med (2008) 1.61
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol Cell (2011) 1.55
Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol (2006) 1.49
Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci U S A (2010) 1.48
Sorting out functions of sirtuins in cancer. Oncogene (2013) 1.47
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem (2008) 1.46
The dual role of sirtuins in cancer. Genes Cancer (2011) 1.45
Calorie restriction and the exercise of chromatin. Genes Dev (2009) 1.44
SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet (2011) 1.41
SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta (2009) 1.41
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci U S A (2008) 1.36
Functional interplay between acetylation and methylation of the RelA subunit of NF-kappaB. Mol Cell Biol (2010) 1.36
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Mol Cell Biol (2011) 1.35
Epigenetic diet: impact on the epigenome and cancer. Epigenomics (2011) 1.33
Sirtuin/Sir2 phylogeny, evolutionary considerations and structural conservation. Mol Cells (2009) 1.27
Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing and promotes tumour cell motility and invasion. EMBO J (2010) 1.27
Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia (2009) 1.25
Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci (2013) 1.25
Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol (2013) 1.24
Concepts of epigenetics in prostate cancer development. Br J Cancer (2008) 1.24
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Epigenetic alterations in aging. J Appl Physiol (1985) (2010) 1.20
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol (2009) 1.19
SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci U S A (2010) 1.19
Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res (2008) 1.18
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet (2008) 1.16
Modulations of hMOF autoacetylation by SIRT1 regulate hMOF recruitment and activities on the chromatin. Cell Res (2011) 1.15
Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med (2010) 1.14
Complex epigenetic regulation of engrailed-2 (EN-2) homeobox gene in the autism cerebellum. Transl Psychiatry (2013) 1.12
A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. FASEB J (2012) 1.11
Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1. Mol Med (2012) 1.09
Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget (2012) 1.08
Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res (2008) 1.05
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. J Mammary Gland Biol Neoplasia (2010) 1.02
Cancer as a manifestation of aberrant chromatin structure. Cancer J (2007) 1.01
Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS One (2012) 1.00
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol (2009) 1.00
Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model. PLoS One (2013) 0.98
Mammalian Sirt1: insights on its biological functions. Cell Commun Signal (2011) 0.98
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis (2013) 0.96
Synergism between DNA methylation and macroH2A1 occupancy in epigenetic silencing of the tumor suppressor gene p16(CDKN2A). Nucleic Acids Res (2010) 0.96
Could Sirt1-mediated epigenetic effects contribute to the longevity response to dietary restriction and be mimicked by other dietary interventions? Age (Dordr) (2009) 0.95
p30 DBC is a potential regulator of tumorigenesis. Cell Cycle (2009) 0.95
Global heterochromatin loss: a unifying theory of aging? Epigenetics (2012) 0.95
Polyamine analogues targeting epigenetic gene regulation. Essays Biochem (2009) 0.95
Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc Natl Acad Sci U S A (2010) 0.94
Epigenetic changes in colorectal cancer. Chin J Cancer (2011) 0.94
High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients. Sci Rep (2014) 0.93
Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics (2008) 0.93
SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27. Mol Cancer Res (2014) 0.93
SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med (2014) 0.93
Loss of a single Hic1 allele accelerates polyp formation in Apc(Δ716) mice. Oncogene (2011) 0.93
Deacetylation by SIRT1 Reprograms Inflammation and Cancer. Genes Cancer (2013) 0.92
The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer (2013) 0.92
Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol (2011) 0.91
Sirtuins, metabolism, and cancer. Front Pharmacol (2012) 0.91
SirT1 brings stemness closer to cancer and aging. Aging (Albany NY) (2011) 0.90
Proinsulin C-peptide regulates ribosomal RNA expression. J Biol Chem (2009) 0.90
SIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress. Genes Cancer (2013) 0.89
Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Res Treat (2012) 0.89
Sirtuin1 (Sirt1) promotes cortical bone formation by preventing β-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem (2014) 0.88
Sirtuins in epigenetic regulation. Chem Rev (2015) 0.88
Diverse roles of SIRT1 in cancer biology and lipid metabolism. Int J Mol Sci (2015) 0.88
Gastric cancer cell lines induced by trichostatin A. World J Gastroenterol (2008) 0.88
Role of SIRT1 in regulation of epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis. Mol Cancer (2014) 0.87
Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase (TERT) gene in hepatocellular carcinoma cells. PLoS One (2014) 0.86
Common features of chromatin in aging and cancer: cause or coincidence? Trends Cell Biol (2014) 0.86
SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol Endocrinol (2013) 0.86
Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One (2015) 0.86
Methylation Profiling of Multiple Tumor Suppressor Genes in Hepatocellular Carcinoma and the Epigenetic Mechanism of 3OST2 Regulation. J Cancer (2015) 0.83
MPP8 and SIRT1 crosstalk in E-cadherin gene silencing and epithelial-mesenchymal transition. EMBO Rep (2015) 0.83
Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity. Open Biol (2013) 0.82
Double-strand breaks and the concept of short- and long-term epigenetic memory. Chromosoma (2010) 0.82
The sirtuins in the pathogenesis of cancer. Clin Epigenetics (2010) 0.81
SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis (2013) 0.81
Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells. PLoS One (2014) 0.81
Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics (2016) 0.80
The apoptotic effects of sirtuin1 inhibitor on the MCF-7 and MRC-5 cell lines. Res Pharm Sci (2013) 0.80
Role of sirtuins in stem cell differentiation. Genes Cancer (2013) 0.79
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature (2000) 20.54
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (1999) 20.34
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (2004) 17.38
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J (2004) 11.00
Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature (2004) 10.36
Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature (2004) 10.32
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
The Sir2 family of protein deacetylases. Annu Rev Biochem (2004) 9.28
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Genetic pathways that regulate ageing in model organisms. Nature (2000) 8.19
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J (2002) 6.37
Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature (2003) 6.25
Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem (2002) 6.15
Sir2 links chromatin silencing, metabolism, and aging. Genes Dev (2000) 5.95
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell (2004) 5.37
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science (2004) 4.61
Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A (2005) 4.57
Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat Genet (2002) 4.36
Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing. Nat Genet (2002) 3.91
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res (2005) 2.94
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol (2004) 2.33
Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell (2005) 2.31
Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A (2001) 2.23
Sir2 regulates histone H3 lysine 9 methylation and heterochromatin assembly in fission yeast. Curr Biol (2003) 2.12
Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression. J Biol Chem (2003) 1.93
CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol (1999) 1.79
Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res (1994) 1.72
Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res (2002) 1.45
SIR2 is required for polycomb silencing and is associated with an E(Z) histone methyltransferase complex. Curr Biol (2004) 1.39
Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol (2002) 1.36
BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch Biochem Biophys (2005) 1.30
E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. Clin Cancer Res (2000) 1.26
The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet (2005) 1.12
Inhibitors of Sir2: evaluation of splitomicin analogues. J Med Chem (2004) 1.04
Gene silencing: two faces of SIR2. Curr Biol (2000) 1.04
Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res (2001) 1.02
Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells. J Biol Chem (2000) 0.99
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
RefSeq: an update on mammalian reference sequences. Nucleic Acids Res (2013) 7.29
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet (2008) 4.87
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet (2009) 3.33
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A (2007) 3.23
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05
Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell (2011) 3.03
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Detection of clinically relevant exonic copy-number changes by array CGH. Hum Mutat (2010) 2.93
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle (2007) 2.55
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol (2004) 2.41
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Bacterial artificial chromosome-emulation oligonucleotide arrays for targeted clinical array-comparative genomic hybridization analyses. Genet Med (2008) 2.36
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22
Current status and new features of the Consensus Coding Sequence database. Nucleic Acids Res (2013) 2.19
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
Identification of de novo copy number variants associated with human disorders of sexual development. PLoS One (2010) 2.14
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
A novel 6C assay uncovers Polycomb-mediated higher order chromatin conformations. Genome Res (2008) 2.10
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 2.04
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res (2003) 2.03
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03